Georgia is currently home to 1992 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention
NCT05701865
Recruiting
The goal of this experimental study is to examine the effect of alcohol, gender, and bystander attitudes on bystander barriers and sexual violence intervention among young adult men and women (age 21-20). The main questions it aims to answer are: Does alcohol intoxication and gender influence bystander barriers and sexual violence intervention? Does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among men, compared to women? Does alcohol intoxi... Read More
Gender:
All
Ages:
Between 21 years and 30 years
Trial Updated:
03/23/2023
Locations: Georgia State University, Atlanta, Georgia
Conditions: Alcohol Intoxication
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
All
Ages:
All
Trial Updated:
03/23/2023
Locations: Clinical Trial Site, Atlanta, Georgia
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553
Recruiting
This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent influenza vaccine in patients with Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will be treated with anifrolumab in addition to standard of care lupus treatments and 10 will receive only standard of care medications. All will receive influenza vaccine.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/21/2023
Locations: Piedmont Hospital, Atlanta, Georgia
Conditions: Systemic Lupus Erythematosus (SLE)
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Healthcare of Atlanta, Emory, Atlanta, Georgia
Conditions: Langerhans Cell Histiocytosis
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Breast Cancer
Register for Updates
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
NCT04832477
Recruiting
The proposed research aims to assess the multiple forms and paths of stigma and substance use as they relate to pre-exposure prophylaxis (PrEP) use for HIV prevention. How stigma and an evolving public health landscape impact PrEP use among Black sexual minorit men who use substances is unknown. The current application focuses on addressing critical and novel questions to improving the essential building blocks of biomedical prevention approaches by providing crucial information for enhancing in... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/19/2023
Locations: SHARE Project, Atlanta, Georgia
Conditions: HIV Seropositivity, Substance Use, STI, Stigma, Social
Register for Updates
A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine
NCT05743335
Recruiting
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects To identify an optimal dose for the JCXH-221 vaccine in healthy adult subjects To assess the humoral immunogenicity of the JCXH-221 vaccine in healthy adult subjects To characterize the cellular immunogenicity of the JCXH-221 vaccine in healthy adult subjects Participants for Pha... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/16/2023
Locations: Velocity Clinical Research, Savannah, Georgia
Conditions: COVID-19, Infectious Disease
Register for Updates
A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children
NCT02616302
Recruiting
The main aims of the study are to see the side effects of Dexlansoprazole treatment effectiveness of Dexlansoprazole treatment in children having symptomatic nonerosive gastroesophageal reflux disease (GERD). Participants will take Dexlansoprazole by mouth once daily for 12 weeks
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
03/15/2023
Locations: Children's Center for Digestive Health Care, LLC, Atlanta, Georgia
Conditions: Gastroesophageal Reflux Disease (GERD)
Register for Updates
Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence
NCT05771597
Recruiting
Biofeedback therapy is an effective treatment for the management of patients with dyssynergic defecation and constipation, urinary incontinence (UI), and fecal incontinence (FI). It is labor-intensive, costly, requires multiple office or hospital visits, is not easily available to the vast majority of patients in the community, and is not covered by many insurance companies. The purpose of this study is to Evaluate home biofeedback therapy for patients with either constipation and dyssynergic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Fecal Incontinence, Dyssynergic Defecation, Urinary Incontinence
Register for Updates
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
NCT04191330
Recruiting
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHFTM platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/09/2023
Locations: Piedmont Athens Regional Medical Center, Athens, Georgia
Conditions: Heart Failure
Register for Updates
Hydroxyurea Optimization Through Precision Study
NCT03789591
Recruiting
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatric sickle cell clin... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
03/09/2023
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
NCT05763602
Recruiting
The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2023
Locations: Emory University, Atlanta, Georgia
Conditions: Surgical Site Infection
Register for Updates